Central Nervous System Prophylaxis Utilization in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Within a Large Community Health System
Journal of Patient-Centered Research and Reviews · 16.07.2024 · 11 (2) · 81-87
DOI: 10.17294/2330-0698.2060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Patient-Centered Research and Reviews, online erschienen am 16.07.2024. Verfasst von Michael J Williams und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Aurora St. Luke's Medical Center, Advocate Health, Milwaukee, WI. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
The impact of central nervous system (CNS) prophylaxis in diffuse large B-cell lymphoma (DLBCL) is contentious. The CNS International Prognostic Index (IPI) calculator offers prognostic guidance in identifying those patients who may be at highest risk of disease progression or relapse to the CNS. However, it is unclear whether this tool has guided clinician decision-making in a real-world setting. Studies have suggested that CNS prophylaxis may not offer clinically significant benefit in terms of preventing CNS disease progression. Given this, we investigated the utilization of CNS prophylaxis within our own population and documentation of the CNS-IPI score.
Methods
We retrospectively evaluated patients with newly diagnosed DLBCL between January 1, 2014, and December 31, 2017. Patients were assessed for receipt of CNS prophylaxis in the form of intrathecal (IT) chemotherapy and/or high-dose intravenous (IV) methotrexate. CNS-IPI scores were calculated for all patients who received CNS prophylaxis or those who experienced CNS disease. Long-term outcomes at five years from diagnosis included CNS progression/relapse and survival.
Results
Of 234 patients who met criteria, 20 (8.6%) received either IV methotrexate or IT chemotherapy; most received IT methotrexate. No patients in the IT prophylaxis group developed CNS disease, while two of eight IV methotrexate patients experienced CNS disease involvement. The incidence of CNS progression was 3.7% in the no prophylaxis group and 10% in those who received prophylaxis.
Conclusions
This study revealed low utilization of CNS prophylaxis and CNS-IPI documentation in a community hospital system. Given large differences between groups, claims of CNS prophylaxis efficacy are unable to be made. CNS relapse rates were consistent with existing literature and promote continued evaluation of the utility of current CNS prophylaxis approaches in DLBCL. New unambiguously effective therapeutic approaches are needed and may encourage a higher rate of standardized use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Services, Aurora St. Luke's Medical Center, Advocate Health, Milwaukee, WI.
- Aurora Cancer Care, Aurora St. Luke's Medical Center, Advocate Health, Milwaukee, WI.
- Providence Cancer Institute, Portland, OR.
- Tempus AI, Chicago, IL.
Zitieren
APA
Williams, M. J., Atienza, S. D., Aranda, R. H., Flint, K. B., Sana, S., Medlin, S. C., Gul, Z., Sanchez, F. A., & Thompson, M. A. (2024). Central Nervous System Prophylaxis Utilization in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Within a Large Community Health System. Journal of Patient-Centered Research and Reviews, 11(2), 81-87. https://doi.org/10.17294/2330-0698.2060
Vancouver
Williams MJ, Atienza SD, Aranda RH, Flint KB, Sana S, Medlin SC, et al. Central Nervous System Prophylaxis Utilization in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Within a Large Community Health System. Journal of Patient-Centered Research and Reviews. 2024;11(2):81-87. doi:10.17294/2330-0698.2060
BibTeX
@article{Williams2024,
author = {Williams, Michael J and Atienza, Sol D and Aranda, Renee H and Flint, Kayleigh B and Sana, Sherjeel and Medlin, Stephen C and Gul, Zartash and Sanchez, Federico A and Thompson, Michael A},
title = {Central Nervous System Prophylaxis Utilization in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Within a Large Community Health System},
journal = {Journal of Patient-Centered Research and Reviews},
year = {2024},
volume = {11},
number = {2},
pages = {81--87},
doi = {10.17294/2330-0698.2060}
}
EUVIMED